NEO vs BLLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NEO · NeoGenomics$14.82 ▼ 1.79%
BLLN · BillionToOne$89.92 ▼ 0.31%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NEO +27.6%
- BLLN -25.0%
Head to head
| Metric | NEO | BLLN |
|---|---|---|
| Price | $14.82 | $89.92 |
| Change today | ▼ 1.79% | ▼ 0.31% |
| Market cap | $1.92B | $4.30B |
| Return, 3 months | -9.7% | -7.0% |
| Return, year to date | +26.0% | +9.9% |
| Return, 1 year | +29.1% | -18.3% |
| P/E (TTM) | – | 93.2 |
| P/B | 2.4 | 7.6 |
| P/E percentile vs own 5y | 5th | 46th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +11.4% | +47.2% |
| Net profit growth (YoY) | +72.2% | +204.5% |
| Gross margin | 44.8% | 71.4% |
| Operating margin | -6.2% | 10.2% |
| Net margin | -4.1% | 10.5% |
| Return on equity | -3.9% | 28.1% |
| Analyst target vs. price | +66.7% | +46.4% |
| Analyst buy share | 78% | 100% |
| RSI (14) | 34 | 30 |
| 30-day volatility | 43.0% | 51.2% |
| Max drawdown, 1 year | -45.6% | -50.8% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BLLN is the largest of the group by market value.
- NEO has returned the most over the past year.
- BLLN is growing revenue fastest.
- BLLN keeps the most profit per dollar of sales.
- NEO has been the calmest stock over the last 30 days.